

## 「藥學倫理案例探析」課程大綱

課程名稱：藥學倫理案例探析 Case Studies in Pharmacy Ethic

授課教師：蔡耀明、林珍芳

學分數：3學分

授課年度：一〇八學年度第二學期

上課時間：星期三 (15:30-18:20)

教室：博雅201

Office hours: 星期三 (1:20-3:10), 星期五 (4:30-5:20), @台大水源校區哲學系館 515 (台北市思源街18號。)

Office hours: 星期二(3:30-5:00), 星期四 (3:30-5:00), @台大城中校區水森藥學系館206 (臺北市中正區10050林森南路33號。)

電子信箱：[tsaiyt@ntu.edu.tw](mailto:tsaiyt@ntu.edu.tw) (蔡耀明); [zflin@ntu.edu.tw](mailto:zflin@ntu.edu.tw) (林珍芳)

網站：<http://homepage.ntu.edu.tw/~tsaiyt/index.html> (蔡耀明);

<http://rx.mc.ntu.edu.tw/myDOP/SCENE/FACULTY/facultyview.php?malangue=&rub=faculty/1//c4ca4238a0b923820dcc509a6f75849b16239055faWf9L3AdnhyU> (林珍芳);

<https://www.facebook.com/djkjflin> (林珍芳)

### 【課程概述】

本課程就生命倫理、醫學倫理、與對藥學倫理，介紹學理，尤其佛學的視角，並且以實際的案例進行廣泛的思考與探討。所探討的藥學倫理議題，包括行善、不傷害、公平正義、尊重自主、誠信以及忠實等。

### 【課程目標】

本課程之目的為培養同學由不同的觀點及佛法觀點，探討藥學倫理議題，對於個人的生命觀與面對的藥學倫理議題，有更深層的思考與反省。

### 【課程要求】

1. 本課程為大學部一般的導論與討論課。學員應預先研讀本課程大綱所列的主要的課程材料，在課堂上積極參與討論，以及按時完成學期作業。每一進度單元所列的「延伸的參考材料」，多少皆具參考價值，並不硬性規定必讀。
2. 分組討論為課程活動重要的一環，特色在於提供論題導向的學習；學員可藉以更深入思索閱讀的材料與講授的內容，並且面對論題，培養獨到思考、理性分析、言辭表達、和相互溝通的能力。整個學期從第3-15週，安排11次的分組討論，由5:30-6:20 pm.,如「課程進度」所列。有關分組討論的確切安排、討論方式、與評量辦法，由教學助理說明。

### 【教材及參考書目】

詳如「課程進度」所列。

### 【成績評量方式】

平時表現45%、分組討論45%、期末報告10%。

1. 平時表現 45% 為敦促學員出席上課以落實學習成效，出缺席狀況與課程投入情形，佔 45%。然而，4 次未出席，依學校規定，學期成績不及格。
2. 分組討論 45% 本課程重視學員確實參與分組討論之進行，包含 11 次分組討論課之參與、預先準備至少 2 次各 2 頁的發言書面稿（主修哲學或藥學者則為 3 頁）、口頭報

告、相互討論。

3. 期末報告 10% 在第十六週時，全班共聚一堂，每一位修課學員皆應繳交書面稿，而以志願或抽籤的方式，在課堂上輪流發表口頭報告，以及相互討論。主修哲學或藥學者，請繳交 5 頁的書面稿，非主修哲學或藥學者，請繳交 4 頁的書面稿。學期報告請將分組討論至少 2 次的書面稿，以聚焦、濃縮、或連貫的方式，更為深入地整理為精華版而成。

不論是分組討論，或是學期報告，書面稿應設定主題為焦點，言之有物，註明根據之出處，並且顯示思辨之努力，宜避免抄襲或空洞堆砌之言。書面稿經查核若為抄襲（如由網絡資料剪貼而成，或書本節錄但未註明出處），一經確定，將至多給予 50 分之成績。

### 【課程進度】

第 1 週 2020/03/04 [單元主題]：課程介紹／人生、醫藥、倫理、宗教：由用藥帶出用藥與醫療之倫理面向與宗教面向（現場投影片）／何謂倫理與道德？／倫理考量之世界觀（蔡老師主講）

何謂倫理與道德？

\* 蔡耀明，〈以《大寶積經·寶梁聚會·阿蘭若比丘品》為依據的動物倫理實踐〉（第一節、緒論），收錄於《2015 星雲大師人間佛教理論實踐研究》，程恭讓、釋妙凡主編，（高雄：佛光文化事業，2016 年 3 月），頁 557.

倫理考量之世界觀

\* 蔡耀明，〈以《大寶積經·寶梁聚會·阿蘭若比丘品》為依據的動物倫理實踐〉（第二節、總括論述：由佛教的生命世界觀帶出動物觀），頁 559-565.

第 2 週 2020/03/11 [單元主題]：(林老師主講)

#### **A Model for Ethical Problem Solving**

Case1-1 Reporting a Possibly Lethal Error: Who Needs to Know?

#### **Values in Health and Illness**

Case2-1 Over-the-Counter Diet Pills

Case2-2 Managing Dental Pain

#### **What is the Source of Moral Judgments**

Case3-1 Should a Pharmacist Perform an Activity That Is “Discouraged”?

Case3-2 Whether to Dispense a Potentially Lethal Drug

Case3-3 Respecting the Wishes of a Dying Patient

Case3-4 A Medication Error on the Oncology Unit: Who Has the Final Word?

#### **Benefiting the Patients and Others: The Duty to Do Good and Avoid Harm**

Case4-1 A Matter of Priorities: A Patient Who Chooses to Reduce Antihypertensive Medication

Case4-2 The Benefits and Harms of High-Dose Chemotherapy

Case4-3 When the Exception Breaks the Rule: Charitable Use of Outdated Drugs

Case4-5 The Interests of the Patient Versus His Family: Burdens on the Caregiver  
**Robert Veatch and et al., *Case Studies in Pharmacy Ethics*, 3<sup>rd</sup> Edition, Oxford: Oxford University Press, 2017, pp. 19-72.**

第3週 2020/03/18〔單元主題〕：Four Questions of Ethics (蔡老師主講)／第一次討論

\* **Robert Veatch and et al., “Introduction: Four Questions of Ethics,” *Case Studies in Pharmacy Ethics*, 3<sup>rd</sup> Edition, Oxford: Oxford University Press, 2017, pp. 1-16.**

〔延伸的參考材料〕

\* Laura Bernhardt, *Theory and Practice: A Primer for Students of Applied Ethics*, 2<sup>nd</sup> ed., CreateSpace, 2017.

\* Robert Holmes, *Introduction to Applied Ethics*, London: Bloomsbury, 2018.

Larry May, Jill Delston (eds.) *Applied Ethics: A Multicultural Approach*, 6<sup>th</sup> ed., New York: Routledge, 2017.

\* Carla Stanford, *Valerie Connor, Applied Law & Ethics for Health Professionals*, 2<sup>nd</sup> ed., Burlington: Jones & Bartlett Learning, 2020.

第4週 2020/03/25〔單元主題〕：(林老師主講)／第二次討論

#### **Justice: The Allocation of Health Resources**

Case5-2 Justice in Paying for Compassionate Use Pharmaceuticals

Case5-4 Compromising the Welfare of Others: Obesity and Allocation of a Scarce Drug

Case5-7 Justice Versus Fidelity

#### **Autonomy**

Case6-1 The Partially Competent Patient

Case6-4 Overriding Patient Autonomy: Hiding the Side Effects of Chemotherapy

Case6-5 Overriding Patient Autonomy (to Save a Life)

#### **Veracity: Dealing Honestly with Patients**

Case7-1 The Duty to Disclose Doubtful Information

Case7-2 Placebos for Addiction Withdrawal

Case7-3 Reporting a Colleague’s Innocent Mistake

Case7-5 Refusing to Learn the Risks of Chemotherapy

Case7-6 When the Family Asks Not to Tell

Case7-7 The Right to Health Records

**Robert Veatch and et al., *Case Studies in Pharmacy Ethics*, 3<sup>rd</sup> Edition, Oxford: Oxford University Press, 2017, pp. 80-125.**

第5週2020/04/01〔單元主題〕：溫書假

第6週2020/04/08〔單元主題〕：Buddhist Ethics (蔡老師主講)／第三次討論

\* **Graham Priest, “Chapter 5: Buddhist Ethics: A Perspective,” *A Mirror Is for Reflection: Understanding Buddhist Ethics*, edited by Jake Davis, New York: Oxford University Press, 2017, pp. 92-108.**

〔延伸的參考材料〕

\* Christopher Gowans, “Chapter 3: Buddhist Moral Thought and Western Moral Philosophy,” *A Mirror Is for Reflection: Understanding Buddhist Ethics*, edited by Jake Davis, New York: Oxford University Press, 2017, pp. 53-69.

\* Damien Keown, “Buddhist Bioethics,” *The Cambridge Textbook of Bioethics*, edited by A. M. Viens, Cambridge: Cambridge University Press, 2008, pp. 391-396.

\* Damien Keown, “Chapter 1: ‘It’s Ethics, Jim, but Not as We Know It’: Reflections on the Absence of Moral Philosophy in Buddhism,” *A Mirror Is for Reflection: Understanding Buddhist Ethics*, edited by Jake Davis, New York: Oxford University Press, 2017, pp. 17-32.

第7週2020/04/15〔單元主題〕：(林老師主講)／第四次討論

### **Fidelity: Promise Keeping and Confidentiality**

Case8-1 Keeping a Promise to a Medical Colleague

Case8-3 The Policeman with Bipolar Disorder: When Others May Be Harmed

Case8-4 Careless Parenteral Preparation: Marginally Competent Colleagues

Case8-5 The Impaired Colleague: The Colleague in an Emotional Crisis

Case8-6 Dishonest Colleagues: Intentionally Shorting Tablet Counts

**Robert Veatch and et al., *Case Studies in Pharmacy Ethics*, 3<sup>rd</sup> Edition, Oxford: Oxford University Press, 2017, pp. 127-144.**

第 8 週 2020/04/22〔單元主題〕：Lessons for the Health-care Practitioner from Buddhism (蔡老師主講)／第五次討論

\* **Sanjay Kalra and et al., “Lessons for the Health-care Practitioner from Buddhism,” *Indian Journal of Endocrinology and Metabolism* 22/6 (Nov-Dec 2018): 812-817.** ([http://www.ijem.in/temp/IndianJEndocrMetab226812-7422513\\_203705.pdf](http://www.ijem.in/temp/IndianJEndocrMetab226812-7422513_203705.pdf))

第9週2020/04/29〔單元主題〕：(林老師主講)／第六次討論

### **Avoidance of Killing**

Case9-1 Prescriptions for Suicide: Forming a Policy for Pharmacy

Case9-2 Deciding Whether to Fill a Lethal Prescription

Case9-3 The ALS Patients: Does Voluntary Choice Justify Terminal Sedation

Case9-4 Withdrawing an Antibiotics: Is It Active Killing?

Case9-5 Unintended but Foreseen Killing with Morphine

Case9-6 Can an Antibiotic Be an Extraordinary Means of Saving Life?

Case9-7 Assisted Suicide and Chronic Depression

**Robert Veatch and et al., *Case Studies in Pharmacy Ethics*, 3<sup>rd</sup> Edition, Oxford: Oxford University Press, 2017, pp. 144-165.**

第10週2020/05/06〔單元主題〕：Illness, Cure, and Care (蔡老師主講)／第七次討論

\* **Dhivan Thomas Jones, “Illness, Cure, and Care: Selections from the Pāli Canon,” *Buddhism and Medicine: An Anthology of Premodern Sources*, edited by C. Pierce**

**Salguero, New York: Columbia University Press, 2017, pp. 3-11.**

〔延伸的參考材料〕

\* C. Pierce Salguero, "Toward a Global History of Buddhism and Medicine," *Buddhist Studies Review* 32/1 (2015): 35-61.

第11週2020/05/13〔單元主題〕：(林老師主講)／第八次討論

**Abortion, Sterilization, and Contraception**

Case10-1 Abortion for Teratogenic Indications

Case10-3 Abortion to Save a Pregnant Woman's Life

Case10-4 Abortion for the Mentally Incapacitated Patient

Case10-6 Sterilization of an Economically Deprived Woman

Case10-7 Biased Counseling: Teaching About Birth Control

Case10-8 Transdermal Contraceptive Patches

**Genetics, Birth, and the Biological Revolution**

Case11-1 Genetic Counseling: Explaining Ambiguous Results

Case11-2 Disclosure of Unanticipated Findings

Case11-4 In Vitro Fertilization: Assessing a New Technology

Case11-5 Embryo Biopsy

Case11-6 Surrogate Motherhood: Medical Miracle or Exploitation of Women?

Case11-7 Genetic Engineering

**Robert Veatch and et al., *Case Studies in Pharmacy Ethics*, 3<sup>rd</sup> Edition, Oxford: Oxford University Press, 2017, pp. 173-215.**

第12週2020/05/20〔單元主題〕：Help for the Sick, Dying and Misbegotten (蔡老師主講)／第九次討論

\* **Gregory Schopen, "Help for the Sick, Dying and Misbegotten: A Sanskrit Version of the Sūtra of Bhaisajyaguru," *Buddhism and Medicine: An Anthology of Premodern Sources*, edited by C. Pierce Salguero, New York: Columbia University Press, 2017, pp. 235-251.**

〔延伸的參考材料〕

\* 《金光明最勝王經·除病品第二十四》(T. 665, vol. 16, pp. 447b-448c)；《金光明最勝王經·長者子流水品第二十五》(T. 665, vol. 16, pp. 448c-450c)。

第13週2020/05/27〔單元主題〕：(林老師主講)／第十次討論

**Mental Health and Behavior Control**

Case12-1 Mentally Ill or Just a Troublemaker? The Concept of Mental Illness

Case12-3 A Compulsion to Kill: People Who Are Mentally Ill and Third-Party Interests

**Formularies and Drug Distribution Systems**

Case13-2 Antibiotics for a Child's Otitis Media

Case13-3 Marginal Benefit from an Additional Antiemetic Agent

Case13-4 Overriding Formularies: Therapeutic Equivalents That Cause Different Side Effects

Case13-5 Conflict of Interest on a P&T Committee

**Robert Veatch and et al., *Case Studies in Pharmacy Ethics*, 3<sup>rd</sup> Edition, Oxford: Oxford University Press, 2017, pp. 217-251.**

第14週2020/06/03〔單元主題〕：翻轉學習（由教學助理說明進行方式）

第15週2020/06/10〔單元主題〕：(林老師主講)／第十一次討論

**Consent and the Right to Refuse Treatment**

Case16-1 Therapeutic Privilege: The Case of the Placebo Narcotic

Case16-2 Explaining Phenytoin Side Effects: The Problem of Adequate Disclosure

Case16-3 Consenting to the Risks of an Antipsychotics: Capacity to Consent

Case16-5 Consent for Patients Who Are Incompetent

**Death and Dying**

Case17-1 His Brain is Gone, but Is He Dead?

Case17-2 Who Decides What Counts as “Comfort Care”?

Case17-3 May a Residential Facility Director Refuse Life Support for a Resident?

Case17-4 Parents Who Refuse Life Support for Their Baby

Case17-5 Futile Treatment: Diagnostic Surgery on a Man Who Appears to Be Dying

**Robert Veatch and et al., *Case Studies in Pharmacy Ethics*, 3<sup>rd</sup> Edition, Oxford: Oxford University Press, 2017, pp. 299-337.**

第16週2020/06/17〔單元主題〕：期末報告與相互討論（依據台大教務處公文如此設置）

第17週2020/06/24〔單元主題〕：no class meeting（自主學習，依據台大教務處公文如此設置）

\* 屈大成（編著），《《四分律·藥犍度》注釋》（台北：佛陀教育基金會）。

(<http://ftp.budaedu.org/publish/C4/CH42/CH420-10-01-001.PDF>)

〔延伸的參考材料〕

\* 《四分律·藥犍度》，姚秦·佛陀耶舍（Buddhayaśas）、竺佛念譯，T. 1428, vol. 22, pp. 866c—877c.

\* C. Pierce Salguero, “Understanding the *Dosa*: A Summary of the Art of Medicine from the *Sūtra of Golden Light*,” *Buddhism and Medicine: An Anthology of Premodern Sources*, edited by C. Pierce Salguero, New York: Columbia University Press, 2017, pp. 30-40.

\* J. E. E. Pettit, “Food and Medicine in the Chinese Vinayas: Daoxuan’s *Emended Commentary on Monastic Practices from the Dharmaguptaka Vinaya*,” *Buddhism and Medicine: An Anthology of Premodern Sources*, edited by C. Pierce Salguero, New York: Columbia University Press, 2017, pp. 130-136.

〔延伸的主題〕透過禪修之療癒

\* 《雜阿含經·第 540 經》(T. 99, vol. 2, p. 140b-c) 。 Cf. Bhikkhu Bodhi (tr.), “SN 52.10,” *The Connected Discourses of the Buddha*, Boston: Wisdom, 2000, pp. 1757-1758.

\* 《增壹阿含經·等法品第三十九·第 6 經》(T. 125, vol. 2, p. 731a-b) 。 Cf. Bhikkhu Bodhi (tr.), “SN 46.16,” *The Connected Discourses of the Buddha*, Boston: Wisdom, 2000, pp. 1581-1582; Bhikkhu Bodhi (tr.), “AN 10.60,” *The Numerical Discourses of the Buddha: A Translation of the Anguttara Nikāya*, Boston: Wisdom, 2012, pp. 1411-1415.

[ 延伸的參考材料 ]

\* Anālayo, “The Healing Potential of the Awakening Factors in Early Buddhist Discourse,” *Buddhism and Medicine: An Anthology of Premodern Sources*, edited by C. Pierce Salguero, New York: Columbia University Press, 2017, pp. 12-19.

第18週2020/07/01 [ 單元主題 ] : no class meeting (自主學習, 依據台大教務處公文如此設置)

### **Health Insurance, Health System Planning, and Rationing**

Case14-5 The \$300,000 Marginal Treatment

Case14-6 Insuring Off-Label Pain Relief

### **Experimentation on Human Subjects**

Case15-1 An Experiment of Last Resort: Calculating Risks and Benefits

Case15-3 Recruiting Subjects from the Clinic for Patients Who Are Indigents

Case15-4 Profiting from Enrolling Subjects in Research

Case15-5 Consent for Randomized Assignment of ACE Inhibitors

**Robert Veatch and et al., *Case Studies in Pharmacy Ethics*, 3<sup>rd</sup> Edition, Oxford: Oxford University Press, 2017, pp. 270-298.**